☰

Catherine Beauchemin - Publications

Affiliations: 
Physics Ryerson University, Toronto, Ontario, Canada 
Tree Info Similar researchers PubMed Report error

41 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Kieran TJ, Sun X, Maines TR, Beauchemin CAA, Belser JA. Exploring associations between viral titer measurements and disease outcomes in ferrets inoculated with 125 contemporary influenza A viruses. Journal of Virology. e0166123. PMID 38240592 DOI: 10.1128/jvi.01661-23  0.453
2023 Quirouette C, Cresta D, Li J, Wilkie KP, Liang H, Beauchemin CAA. The effect of random virus failure following cell entry on infection outcome and the success of antiviral therapy. Scientific Reports. 13: 17243. PMID 37821517 DOI: 10.1038/s41598-023-44180-w  0.485
2023 Cresta D, Warren DC, Quirouette C, Smith AP, Lane LC, Smith AM, Beauchemin CAA. Correction: Time to revisit the endpoint dilution assay and to replace the TCID50 as a measure of a virus sample's infection concentration. Plos Computational Biology. 19: e1010877. PMID 36719876 DOI: 10.1371/journal.pcbi.1010877  0.307
2023 Creager HM, Kieran TJ, Zeng H, Sun X, Pulit-Penaloza JA, Holmes KE, Johnson AF, Tumpey TM, Maines TR, Beauchemin CAA, Belser JA. Utility of Human Data in Risk Assessments of Influenza A Virus Using the Ferret Model. Journal of Virology. e0153622. PMID 36602361 DOI: 10.1128/jvi.01536-22  0.527
2022 Quirouette C, Younis NP, Reddy MB, Beauchemin CAA. Correction: A mathematical model describing the localization and spread of influenza A virus infection within the human respiratory tract. Plos Computational Biology. 18: e1009851. PMID 35120142 DOI: 10.1371/journal.pcbi.1009851  0.432
2021 Cresta D, Warren DC, Quirouette C, Smith AP, Lane LC, Smith AM, Beauchemin CAA. Time to revisit the endpoint dilution assay and to replace the TCID50 as a measure of a virus sample's infection concentration. Plos Computational Biology. 17: e1009480. PMID 34662338 DOI: 10.1371/journal.pcbi.1009480  0.393
2020 Liao LE, Carruthers J, Smither SJ, Weller SA, Williamson D, Laws TR, García-Dorival I, Hiscox J, Holder BP, Beauchemin CAA, Perelson AS, López-García M, Lythe G, Barr J, et al. Quantification of Ebola virus replication kinetics in vitro. Plos Computational Biology. 16: e1008375. PMID 33137116 DOI: 10.1371/journal.pcbi.1008375  0.537
2020 Quirouette C, Younis NP, Reddy MB, Beauchemin CAA. Correction: A mathematical model describing the localization and spread of influenza A virus infection within the human respiratory tract. Plos Computational Biology. 16: e1008424. PMID 33137087 DOI: 10.1371/journal.pcbi.1008424  0.432
2020 Yan AWC, Zhou J, Beauchemin CAA, Russell CA, Barclay WS, Riley S. Quantifying mechanistic traits of influenza viral dynamics using in vitro data. Epidemics. 33: 100406. PMID 33096342 DOI: 10.1016/j.epidem.2020.100406  0.402
2020 Quirouette C, Younis NP, Reddy MB, Beauchemin CAA. A mathematical model describing the localization and spread of influenza A virus infection within the human respiratory tract. Plos Computational Biology. 16: e1007705. PMID 32282797 DOI: 10.1371/journal.pcbi.1007705  0.517
2019 Beauchemin CAA, Kim YI, Yu Q, Ciaramella G, DeVincenzo JP. Uncovering critical properties of the human respiratory syncytial virus by combining in vitro assays and in silico analyses. Plos One. 14: e0214708. PMID 30986239 DOI: 10.1371/journal.pone.0214708  0.498
2018 Handel A, Liao LE, Beauchemin CAA. Progress and trends in mathematical modelling of influenza A virus infections Current Opinion in Systems Biology. 12: 30-36. DOI: 10.1016/J.Coisb.2018.08.009  0.549
2017 Liao LE, Kowal S, Cardenas DA, Beauchemin CAA. Exploring virus release as a bottleneck for the spread of influenza A virus infection in vitro and the implications for antiviral therapy with neuraminidase inhibitors. Plos One. 12: e0183621. PMID 28837615 DOI: 10.1371/journal.pone.0183621  0.409
2017 Dobrovolny HM, Beauchemin CAA. Modelling the emergence of influenza drug resistance: The roles of surface proteins, the immune response and antiviral mechanisms. Plos One. 12: e0180582. PMID 28700622 DOI: 10.1371/journal.pone.0180582  0.625
2017 Beauchemin CA, Miura T, Iwami S. Duration of SHIV production by infected cells is not exponentially distributed: Implications for estimates of infection parameters and antiviral efficacy. Scientific Reports. 7: 42765. PMID 28202942 DOI: 10.1038/srep42765  0.381
2017 Palmer J, Dobrovolny HM, Beauchemin CA. The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patients. Scientific Reports. 7: 40210. PMID 28067324 DOI: 10.1038/srep40210  0.651
2016 Liao LE, Iwami S, Beauchemin CA. (In)validating experimentally derived knowledge about influenza A defective interfering particles. Journal of the Royal Society, Interface. 13. PMID 27881801 DOI: 10.1098/rsif.2016.0412  0.48
2016 Lipsitch M, Barclay W, Raman R, Russell CJ, Belser JA, Cobey S, Kasson PM, Lloyd-Smith JO, Maurer-Stroh S, Riley S, Beauchemin CA, Bedford T, Friedrich TC, Handel A, Herfst S, et al. Viral factors in influenza pandemic risk assessment. Elife. 5. PMID 27834632 DOI: 10.7554/Elife.18491  0.35
2016 Simon PF, de La Vega MA, Paradis É, Mendoza E, Coombs KM, Kobasa D, Beauchemin CA. Avian influenza viruses that cause highly virulent infections in humans exhibit distinct replicative properties in contrast to human H1N1 viruses. Scientific Reports. 6: 24154. PMID 27080193 DOI: 10.1038/srep24154  0.474
2016 Kamal MA, Gieschke R, Lemenuel-Diot A, Beauchemin CA, Smith PF, Rayner CR. Erratum for Kamal et al., A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression. Antimicrobial Agents and Chemotherapy. 60: 1953. PMID 26921415 DOI: 10.1128/AAC.00179-16  0.314
2015 Kamal MA, Gieschke R, Lemenuel-Diot A, Beauchemin CA, Smith PF, Rayner CR. A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression. Antimicrobial Agents and Chemotherapy. PMID 26100715 DOI: 10.1128/AAC.00069-15  0.478
2015 Kakizoe Y, Nakaoka S, Beauchemin CA, Morita S, Mori H, Igarashi T, Aihara K, Miura T, Iwami S. A method to determine the duration of the eclipse phase for in vitro infection with a highly pathogenic SHIV strain. Scientific Reports. 5: 10371. PMID 25996439 DOI: 10.1038/srep10371  0.436
2015 Paradis EG, Pinilla LT, Holder BP, Abed Y, Boivin G, Beauchemin CA. Impact of the H275Y and I223V Mutations in the Neuraminidase of the 2009 Pandemic Influenza Virus In Vitro and Evaluating Experimental Reproducibility. Plos One. 10: e0126115. PMID 25992792 DOI: 10.1371/Journal.Pone.0126115  0.357
2015 Kakizoe Y, Morita S, Nakaoka S, Takeuchi Y, Sato K, Miura T, Beauchemin CA, Iwami S. A conservation law for virus infection kinetics in vitro. Journal of Theoretical Biology. 376: 39-47. PMID 25882746 DOI: 10.1016/j.jtbi.2015.03.034  0.415
2014 Lachaine J, Vachon M, Lambert-Obry V, Beauchemin C. Costs Of Adverse Events Associated With Treatment Of Hepatitis C Virus Infection: An Analysis Using The Quebec Provincial Drug Reimbursement Program Database Value in Health. 17: A272. DOI: 10.1016/J.Jval.2014.03.1584  0.324
2013 Dobrovolny HM, Reddy MB, Kamal MA, Rayner CR, Beauchemin CA. Assessing mathematical models of influenza infections using features of the immune response. Plos One. 8: e57088. PMID 23468916 DOI: 10.1371/journal.pone.0057088  0.645
2013 Lachaine J, Vachon M, Lambert-Obry V, Beauchemin C. Hepatitis C Virus Infection Treatment Completion: An Analysis of the Quebec Provincial Reimbursement Program Database Value in Health. 16: A361. DOI: 10.1016/J.Jval.2013.08.227  0.33
2012 Pinilla LT, Holder BP, Abed Y, Boivin G, Beauchemin CA. The H275Y neuraminidase mutation of the pandemic A/H1N1 influenza virus lengthens the eclipse phase and reduces viral output of infected cells, potentially compromising fitness in ferrets. Journal of Virology. 86: 10651-60. PMID 22837199 DOI: 10.1128/Jvi.07244-11  0.448
2012 Iwami S, Holder BP, Beauchemin CA, Morita S, Tada T, Sato K, Igarashi T, Miura T. Quantification system for the viral dynamics of a highly pathogenic simian/human immunodeficiency virus based on an in vitro experiment and a mathematical model. Retrovirology. 9: 18. PMID 22364292 DOI: 10.1186/1742-4690-9-18  0.493
2011 Holder BP, Simon P, Liao LE, Abed Y, Bouhy X, Beauchemin CA, Boivin G. Assessing the in vitro fitness of an oseltamivir-resistant seasonal A/H1N1 influenza strain using a mathematical model. Plos One. 6: e14767. PMID 21455300 DOI: 10.1371/Journal.Pone.0014767  0.49
2011 Beauchemin CA, Handel A. A review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges ahead. Bmc Public Health. 11: S7. PMID 21356136 DOI: 10.1186/1471-2458-11-S1-S7  0.49
2011 Holder BP, Beauchemin CA. Exploring the effect of biological delays in kinetic models of influenza within a host or cell culture. Bmc Public Health. 11: S10. PMID 21356129 DOI: 10.1186/1471-2458-11-S1-S10  0.497
2011 Holder BP, Liao LE, Simon P, Boivin G, Beauchemin CA. Design considerations in building in silico equivalents of common experimental influenza virus assays. Autoimmunity. 44: 282-93. PMID 21244331 DOI: 10.3109/08916934.2011.523267  0.396
2011 Mitchell H, Levin D, Forrest S, Beauchemin CA, Tipper J, Knight J, Donart N, Layton RC, Pyles J, Gao P, Harrod KS, Perelson AS, Koster F. Higher level of replication efficiency of 2009 (H1N1) pandemic influenza virus than those of seasonal and avian strains: kinetics from epithelial cell culture and computational modeling. Journal of Virology. 85: 1125-35. PMID 21068247 DOI: 10.1128/Jvi.01722-10  0.403
2011 Dobrovolny HM, Gieschke R, Davies BE, Jumbe NL, Beauchemin CA. Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study. Journal of Theoretical Biology. 269: 234-44. PMID 20970433 DOI: 10.1016/j.jtbi.2010.10.017  0.689
2010 Dobrovolny HM, Baron MJ, Gieschke R, Davies BE, Jumbe NL, Beauchemin CA. Exploring cell tropism as a possible contributor to influenza infection severity. Plos One. 5: e13811. PMID 21124892 DOI: 10.1371/journal.pone.0013811  0.684
2009 Craddock TJA, Beauchemin C, Tuszynski JA. Information processing mechanisms in microtubules at physiological temperature: Model predictions for experimental tests Biosystems. 97: 28-34. PMID 19477062 DOI: 10.1016/J.Biosystems.2009.04.001  0.414
2008 Beauchemin CA, McSharry JJ, Drusano GL, Nguyen JT, Went GT, Ribeiro RM, Perelson AS. Modeling amantadine treatment of influenza A virus in vitro. Journal of Theoretical Biology. 254: 439-51. PMID 18653201 DOI: 10.1016/J.Jtbi.2008.05.031  0.574
2006 Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. Kinetics of influenza A virus infection in humans. Journal of Virology. 80: 7590-9. PMID 16840338 DOI: 10.1128/Jvi.01623-05  0.623
2006 Beauchemin C. Probing the effects of the well-mixed assumption on viral infection dynamics. Journal of Theoretical Biology. 242: 464-77. PMID 16650441 DOI: 10.1016/J.Jtbi.2006.03.014  0.582
2005 Beauchemin C, Samuel J, Tuszynski J. A simple cellular automaton model for influenza A viral infections. Journal of Theoretical Biology. 232: 223-34. PMID 15530492 DOI: 10.1016/J.Jtbi.2004.08.001  0.624
Show low-probability matches.